# Neuland Laboratories Ltd (NEULANDLAB)
> Exchange: NSE | Sector: Pharma | ISIN: 

## Price
Current Price: ₹16690
Day Change: +0.4%
52W High: ₹19747
52W Low: ₹11011
Market Cap: ₹21,003 Cr

## Valuation
P/E: 57.7
P/B: 11.2
EPS: ₹283.69
Book Value: ₹1460.99
Dividend Yield: 0%

## Returns
1Y Return: -7.2%

## Profitability
ROE: 0%
ROCE: 25.81%
Debt/Equity: 0.16
Revenue Growth: 136.4%
Profit Growth: 664.9%
EBITDA Margin: 8.82%
Operating Margin: 36.36%

## About
Neuland Laboratories Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Sector: Pharma
Industry: Drug Manufacturers - Specialty & Generic
Sub Industry: Unknown

## Business Model
Overview: Neuland Laboratories Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Source: Derived from stock data
Revenue Streams:
- Domestic formulations
- Exports and regulated markets
- Specialty or institutional sales
Operating Model:
- Develops, manufactures, distributes, or services healthcare products across regulated channels.
- Approvals, product mix, compliance quality, and R&D productivity shape growth.
Recent Context:
- Concall Transcript: Announcement under Regulation 30 (LODR)-Earnings Call Transcript
- Announcement: Announcement under Regulation 30 (LODR)-Newspaper Publication
- BSE Filing: Announcement under Regulation 30 (LODR)-Newspaper Publication

## Access
Current tier: anonymous
More history: Register free to see 8 more years.

## Data Freshness
Quote Updated: 2026-05-21T20:00:03.547Z
Price History Updated: 2026-05-18T22:58:16.193Z
Latest Price History Date: 2026-05-18
Technicals Updated: 2026-05-18T22:58:16.193Z
Quant Updated: 2026-05-18T22:58:16.193Z
Sentiment Updated: 2026-05-18T22:58:16.193Z
Financials Status: current
Financials Updated: 2026-05-18T08:32:13.318Z
Financials Last Attempt: 2026-05-18T08:32:13.318Z
Financials Provider Tried: yahoo
Latest P&L Period: FY25
Latest Balance Sheet Period: FY25
Latest Cash Flow Period: FY25

## P&L (Mar 2016)
Revenue: ₹469 Cr
Operating Profit: ₹67 Cr (OPM 14%)
Net Profit: ₹16 Cr
Tax: ₹25 Cr

## Annual P&L History
Mar 2016: Rev ₹469Cr | PAT ₹16Cr | OPM 14%
Mar 2017: Rev ₹510Cr | PAT ₹27Cr | OPM 16%
Mar 2018: Rev ₹579Cr | PAT ₹47Cr | OPM 18%

## Balance Sheet (Mar 2016)
Total Assets: ₹512 Cr
Total Liabilities: ₹512 Cr
Borrowings: ₹188 Cr
Cash: ₹undefined Cr

## Shareholding
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%
undefined: undefined%

## Board
- Davuluri Rama Mohan Rao, Executive Chairman & Chief Promoter and Member of Scientific Advisory Board
- Davuluri Saharsh Rao, CEO & MD
- Davuluri Sucheth Rao, Executive Vice Chairman
- Abhijit  Majumdar, Chief Financial Officer
- Sharadsrikar Venkatesan Kotturi, Chief Scientific Officer & Member of Scientific Advisory Board

---
Source: rupiya.io/stocks/neulandlab
Disclaimer: For research and education only. Not investment advice.